Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 3, 2022 7:30 AM EDTARCALYST® (rilonacept) net revenue of $27.0 million in Q2 2022
ARCALYST full-year 2022 net revenue expected to be $115 - $130 million
 Upfront and near-term proceeds of $100 million expected from vixarelimab global license agreement
Cash reserves after the close of the vixarelimab global license agreement expected to fund operations into at least 2025 Conference call and webcast scheduled for 8:30 am ETÂ todayÂ
HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) --... More
